http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1408968-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_089360ca4fb7c85389abdcd18342287f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40c9fc99955c034348897aa8a8919a5d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7092 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418 |
| filingDate | 2002-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83243d2a416aa44f079c5f85e16ddffb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b4b85b6601867454212ebe6a7e561a3 |
| publicationDate | 2005-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1408968-B1 |
| titleOfInvention | Receptor-adapted nicotine withdrawal by a combination of atropine, scopolamine, clonidine |
| abstract | Transdermal patch for treating nicotine addiction comprises clonidine or a combination of atropine and scopolamine. ACTIVITY : Antismoking. MECHANISM OF ACTION : Acetylcholine release inhibitor; Noradrenaline release inhibitor. In a trial on 480 patients, who received an intramuscular injection of atropine (0.1 mg) and scopolamine (0.1 mg) followed by an intramuscular injection of atropine (0.1 mg), scopolamine (0.1 mg) and clonidine (0.15 mg) on day 1, after which transdermal therapy was started on day 2 with one clonidine patch and one atropine/scopolamine patch on the upper arm (no concrete details given), the proportion of patients still abstinent after 12 months was 78%, which was up to 50% higher than that achieved by prior art therapies (author references given, but no bibliography). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2095814-A1 |
| priorityDate | 2001-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.